Monitoring gastric cancer progression with circulating tumour DNA

T. Hamakawa, Y. Kukita, Y. Kurokawa, Y. Miyazaki, T. Takahashi, M. Yamasaki, H. Miyata, K. Nakajima, K. Taniguchi, S. Takiguchi, Masaki Mori, Y. Doki, K. Kato

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.

Original languageEnglish
Pages (from-to)352-356
Number of pages5
JournalBritish journal of cancer
Volume112
Issue number2
DOIs
Publication statusPublished - Jan 20 2015
Externally publishedYes

Fingerprint

Stomach Neoplasms
DNA
Neoplasms
High-Throughput Nucleotide Sequencing
Mutation
Biomarkers
Plasma Cells
Disease Progression

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hamakawa, T., Kukita, Y., Kurokawa, Y., Miyazaki, Y., Takahashi, T., Yamasaki, M., ... Kato, K. (2015). Monitoring gastric cancer progression with circulating tumour DNA. British journal of cancer, 112(2), 352-356. https://doi.org/10.1038/bjc.2014.609

Monitoring gastric cancer progression with circulating tumour DNA. / Hamakawa, T.; Kukita, Y.; Kurokawa, Y.; Miyazaki, Y.; Takahashi, T.; Yamasaki, M.; Miyata, H.; Nakajima, K.; Taniguchi, K.; Takiguchi, S.; Mori, Masaki; Doki, Y.; Kato, K.

In: British journal of cancer, Vol. 112, No. 2, 20.01.2015, p. 352-356.

Research output: Contribution to journalArticle

Hamakawa, T, Kukita, Y, Kurokawa, Y, Miyazaki, Y, Takahashi, T, Yamasaki, M, Miyata, H, Nakajima, K, Taniguchi, K, Takiguchi, S, Mori, M, Doki, Y & Kato, K 2015, 'Monitoring gastric cancer progression with circulating tumour DNA', British journal of cancer, vol. 112, no. 2, pp. 352-356. https://doi.org/10.1038/bjc.2014.609
Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M et al. Monitoring gastric cancer progression with circulating tumour DNA. British journal of cancer. 2015 Jan 20;112(2):352-356. https://doi.org/10.1038/bjc.2014.609
Hamakawa, T. ; Kukita, Y. ; Kurokawa, Y. ; Miyazaki, Y. ; Takahashi, T. ; Yamasaki, M. ; Miyata, H. ; Nakajima, K. ; Taniguchi, K. ; Takiguchi, S. ; Mori, Masaki ; Doki, Y. ; Kato, K. / Monitoring gastric cancer progression with circulating tumour DNA. In: British journal of cancer. 2015 ; Vol. 112, No. 2. pp. 352-356.
@article{e3f5aea423eb4f1794d49e876eef324b,
title = "Monitoring gastric cancer progression with circulating tumour DNA",
abstract = "Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.",
author = "T. Hamakawa and Y. Kukita and Y. Kurokawa and Y. Miyazaki and T. Takahashi and M. Yamasaki and H. Miyata and K. Nakajima and K. Taniguchi and S. Takiguchi and Masaki Mori and Y. Doki and K. Kato",
year = "2015",
month = "1",
day = "20",
doi = "10.1038/bjc.2014.609",
language = "English",
volume = "112",
pages = "352--356",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Monitoring gastric cancer progression with circulating tumour DNA

AU - Hamakawa, T.

AU - Kukita, Y.

AU - Kurokawa, Y.

AU - Miyazaki, Y.

AU - Takahashi, T.

AU - Yamasaki, M.

AU - Miyata, H.

AU - Nakajima, K.

AU - Taniguchi, K.

AU - Takiguchi, S.

AU - Mori, Masaki

AU - Doki, Y.

AU - Kato, K.

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.

AB - Background: Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer. Methods: We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status. Results: Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status. Conclusions: ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.

UR - http://www.scopus.com/inward/record.url?scp=84921939213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921939213&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.609

DO - 10.1038/bjc.2014.609

M3 - Article

C2 - 25490524

AN - SCOPUS:84921939213

VL - 112

SP - 352

EP - 356

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -